A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction-Reference-Cited by-全球学者库

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

Published:2020-05-06 Issue:7 Volume:40 Page:1655-1669
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

An Ping¹²^ORCID,Wei Guangyan¹³,Huang Pinzhu¹⁴^ORCID,Li Wenda¹⁵,Qi Xiaolong¹⁶,Lin Yi¹,Vaid Kahini A.¹,Wang Jun⁷,Zhang Shucha⁸,Li Yang⁸,Or Yat Sun⁸,Jiang Li‐Juan⁸,Popov Yury V.¹^ORCID

Affiliation:

1. Divison of Gastroenterology and Hepatology Beth Israel Deaconess Medical CenterHarvard Medical School Boston MA USA

2. Division of Gastroenterology and Hepatology Renmin HospitalWuhan University Wuhan China

3. Department of Radiation Oncology The First Affiliated HospitalSun Yat‐sen University Guangzhou China

4. Department of Colon and Rectum Surgery The Sixth Affiliated HospitalSun Yat-sen University Guangzhou China

5. Department of Hepatobiliary Surger Sun Yat-sen Memorial HospitalSun Yat‐sen University Guangzhou China

6. Institute of Portal Hypertension The First Hospital of Lanzhou University Lanzhou China

7. Division of Neurosurgery Renmin HospitalWuhan University Wuhan China

8. Enanta Pharmaceuticals, Inc. Watertown MA USA

Funder

PSC Partners Seeking a Cure

Beth Israel Deaconess Medical Center

National Natural Science Foundation of China

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.14490

Reference42 articles.

1. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

2. Enhanced liver fibrosis score predicts transplant‐free survival in primary sclerosing cholangitis

3. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases

4. Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies

5. Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular Interactions and Crosstalk Facilitating Biliary Fibrosis in Cholestasis;Cellular and Molecular Gastroenterology and Hepatology;2024-01

2. FXR agonists in NASH treatment;Journal of Hepatology;2023-11

3. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis;JHEP Reports;2023-11

4. Gut microbiota and nonalcoholic fatty liver disease;Kosin Medical Journal;2023-09-30

5. Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis;Journal of Medicinal Chemistry;2023-07-10